CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.
CMD-OPT 模型能够发现一种强效且选择性的 RIPK2 抑制剂，作为治疗急性肝损伤的临床前候选药物
期刊:Acta Pharmaceutica Sinica B
影响因子:14.6
doi:10.1016/j.apsb.2025.05.003
Chen Yong, Yuan Xue, Yan Wei, Zou Yurong, Wei Haoche, Wei Yuhan, Tang Minghai, Chen Yulian, Ma Ziyan, Yang Tao, Liu Kongjun, Xiong Baojian, Hu Xiuying, Yang Jianhong, Chen Lijuan
